Nicox (NICXF)
(Delayed Data from OTC)
$0.44 USD
0.00 (0.00%)
Updated Dec 28, 2023 12:11 PM ET
4-Sell of 5 4
F Value D Growth NA Momentum NA VGM
Brokerage Reports
0 items in cart
Nicox SA [NICXF]
Reports for Purchase
Showing records 41 - 60 ( 120 total )
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Expansion of VYZULTA Commercial Rollout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
NCX 4251 Designated as A Dry Eye Disease Candidate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
4Q21 Financial Highlights Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Mississippi data shows benefit in dry eye
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
3Q21 Financial Highlights Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Adjusting NCX-470 launch timing estimates
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
NCX 470 Protects Retinal Cell in A Preclinical Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
First Half 2021 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Phase 2b Blepharitis Data Reported; Reiterate Buy; Reducing PT to ?12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
NCX-4251 setback sharpens focus on NCX-470
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Continuing to move towards data inflection points
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
VYZULTA Obtains Approval in United Arab Emirates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Phase 2b Blepharitis Trial Completes Enrollment; Data by End-3Q21; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
ZERVIATE Mexican Licensing Deal Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
VYZULTA International Reach Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Patent Allowance Covering VYZULTA in Normal Tension Glaucoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R